Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: results of a multicenter trial. The Flecainide Supraventricular Tachycardia Study Group

The American Journal of Cardiology
J R HopsonM G Kienzle

Abstract

Patients with supraventricular arrhythmias have been safely and effectively treated with flecainide. We conducted an open-label, 20-center trial to define further the safety and efficacy profile of oral flecainide in patients with supraventricular arrhythmias, including atrial tachycardias (ectopic or multifocal), atrial-ventricular tachycardias (reentrant), paroxysmal atrial fibrillation/flutter (PAF), and chronic atrial fibrillation (CAF). Our study population of 151 patients with documented supraventricular arrhythmias requiring treatment included 67 with paroxysmal supraventricular tachycardia (PSVT), 67 with PAF (symptoms < 15 days), and 17 with CAF (symptoms > of = 15 days)> The initial flecainide dose of 100 mg twice daily could be increased by 50 mg bid every 4 days to a maximum of 200 mg twice daily. Patients who were effectively treated could receive flecainide for 1 year. The study was terminated April 26, 1989, in response to interim results reported by the Cardiac Arrhythmia Suppression Trial (CAST). All patients were removed from the study by August 1989. At study termination 87% of PSVT, 73% of PAF, and 56% of CAF patients had improved symptomatically while on flecainide therapy. Eleven patients experienced cardi...Continue Reading

References

Apr 1, 1991·International Journal of Cardiology·V KühlkampL Seipel
Jan 1, 1990·Cardiology·L Mary-Rabine, H E Kulbertus
Aug 10, 1989·The New England Journal of Medicine·UNKNOWN Cardiac Arrhythmia Suppression Trial (CAST) Investigators
Aug 25, 1988·The American Journal of Cardiology·S S KimR Ruffy
Aug 25, 1988·The American Journal of Cardiology·H Neuss, M Schlepper
Jun 1, 1973·The Journal of Clinical Endocrinology and Metabolism·L ShenkmanC S Hollander
Feb 27, 1984·The American Journal of Cardiology·J Morganroth, L N Horowitz
Jul 1, 1993·Pacing and Clinical Electrophysiology : PACE·A W HamerV D Hunt

❮ Previous
Next ❯

Citations

Mar 8, 2014·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Hanney Gonna, Mark M Gallagher
Apr 4, 2001·Acta Ophthalmologica Scandinavica·K IkäheimoM Mäntyjärvi
Jan 13, 1998·Journal of the American College of Cardiology·L A OrejarenaJ J Hayes
Aug 12, 2014·Pediatric Cardiology·Brady S MoffettJeffrey J Kim
Mar 11, 2004·Pacing and Clinical Electrophysiology : PACE·Vicente E ClimentFrancisco Sogorb
Jun 14, 2018·Current Drug Research Reviews·Livia BeraldoJoão M Castaldelli-Maia
Mar 31, 2015·The Cochrane Database of Systematic Reviews·Carmelo Lafuente-LafuenteJoël Belmin
Sep 5, 2019·The Cochrane Database of Systematic Reviews·Lucie ValemboisCarmelo Lafuente-Lafuente
Mar 21, 2009·Journal of Cardiovascular Electrophysiology·Mubashir AhmedM Eyman Mortada
Oct 30, 2010·Pacing and Clinical Electrophysiology : PACE·Han Sang KimSung Soon Kim
May 31, 2013·Journal of Clinical Pharmacology·Samir M SaidRuediger C Braun-Dullaeus
Nov 20, 2016·Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology·Demosthenes G KatritsisJack Rickard
Jul 14, 2010·Experimental Physiology·Yana DautovaChristopher L-H Huang
Feb 2, 2006·British Journal of Hospital Medicine·Bejal Pandya, Pier D Lambiase

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Anti-Arrhythmic Drug Therapies

Anti-arrhythmic drugs are used to prevent abnormal heart rhythms. These medications are used in conditions including, ventricular tachycardia, ventricular fibrillation and atrial fibrillation. Discover the latest research on anti-arrhythmic drug therapies here.

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.